DGC-specific RHOA mutations maintained cancer cell survival and promoted cell migration via ROCK inactivation

missense mutations exist specifically in diffuse type gastric cancers (DGC) and are considered one of the DGC driver genes, but it is not fully understood how mutations contribute to DGC development. Here we examined how mutations affect cancer cell survival and cell motility. We revealed that cell...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncotarget 2018-05, Vol.9 (33), p.23198-23207
Hauptverfasser: Nishizawa, Takashi, Nakano, Kiyotaka, Harada, Aya, Kakiuchi, Miwako, Funahashi, Shin-Ichi, Suzuki, Masami, Ishikawa, Shumpei, Aburatani, Hiroyuki
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:missense mutations exist specifically in diffuse type gastric cancers (DGC) and are considered one of the DGC driver genes, but it is not fully understood how mutations contribute to DGC development. Here we examined how mutations affect cancer cell survival and cell motility. We revealed that cell survival was maintained by specific mutation sites, namely G17, Y42, and L57. Because these functional mutations suppressed MLC2 phosphorylation and actin stress fiber formation, we realized they act in a dominant-negative fashion against the ROCK pathway. Through the same inactivating mechanism that maintained cell survival, mutations also increased cell migration activity. Cell survival and migration studies on ( ) fusions, which are known to be mutually exclusive to mutations, showed that fusions complemented cell survival under knockdown condition and also induced cell migration. Site-directed mutagenesis analysis revealed the importance of the GAP domain and indicated that fusions maintained RHOA in the inactive form. Taken together, these findings show that the inactivation of ROCK would be a key step in DGC development, so ROCK activation might provide novel therapeutic opportunities.
ISSN:1949-2553
1949-2553
DOI:10.18632/oncotarget.25269